TEAD3: The "invisible guardian" of bone health and the "brake valve" of tumor bone metastasis

TEAD3: The "invisible guardian" of bone health and the "brake valve" of tumor bone metastasis

In the "iron bones" of the human body, bones not only support the body, but also serve as mineral warehouses and hematopoietic factories. However, bone metastasis of malignant tumors such as breast cancer and melanoma destroys the bone structure like "gnawing by termites", leading to pathological fractures, severe pain and even paralysis. What is more worrying is that such patients are often accompanied by osteoporosis, forming a vicious cycle of "tumor-bone destruction". Recently, Professor Ma Li's team at the MD Anderson Cancer Center in the United States published a breakthrough study in Nature Communications, revealing the key role of transcription factor TEAD3 in bone homeostasis, providing new ideas for solving this dilemma.

1. The "balance" of bone metabolism: the game between osteoclasts and osteoblasts

Bones are not static "rebars", but are in a dynamic balance of continuous remodeling:

Osteoblasts are like "construction workers", secreting collagen and calcium salts to build new bones;
Osteoclasts are like "demolition teams", dissolving old bone matrix by secreting enzymes such as cathepsin K (CTSK).

In a healthy state, the two are precisely regulated by the "RANK-RANKL-OPG signaling axis". However, when tumor cells colonize in bones, they secrete a large amount of RANKL, activating osteoclast precursors (monocytes/macrophages) to differentiate into multinuclear giant cells, leading to excessive bone absorption. Studies have shown that the number of osteoclasts in the bone metastasis site of tumor patients is 5-10 times that of normal bone tissue, which is the direct culprit of osteolytic lesions.

2. TEAD3: The "molecular switch" of osteoclast differentiation
Ma Li's team found that TEAD3 (TEA domain transcription factor 3) is the "core regulator" of osteoclast lineage specificity, and its mechanism of action can be summarized as a "triple lock":

Specific expression

TEAD3 expression surges 3-5 times during the differentiation of monocytes/macrophages into osteoclasts, while other TEAD family members (such as TEAD1/4) do not change significantly. This lineage specificity makes it a potential target for precision intervention.
Transcription complex formation

TEAD3 forms a complex with NFATC1 (the master control factor of osteoclast differentiation) through its DNA binding domain (TEA domain), directly binds to the promoter region of osteolytic genes such as CTSK and ACP5, and activates transcription. This process is like a "molecular key" opening the "keyhole" of gene expression.
Competitive regulation

Long-chain non-coding RNA MALAT1 acts as a "molecular sponge" and prevents TEAD3 from interacting with NFATC1 by binding to it. When MALAT1 is missing, the free TEAD3-NFATC1 complex increases, leading to upregulation of osteolytic gene expression and enhanced osteoclast activity.
3. Clinical association: "Common targets" from osteoporosis to tumor bone metastasis

The research team revealed the "dual identity" of TEAD3 through single-cell transcriptome sequencing:

Osteoporosis: In osteoclasts of osteoporotic patients, TEAD3 expression is 2.3 times higher than that of non-osteoporotic patients, and is significantly positively correlated with CTSK and ACP5 expression (r=0.78);
Tumor bone metastasis: The TEAD3 level in osteoclasts of breast cancer bone metastasis patients is 1.8 times higher than that of primary bone tumor patients, suggesting that it may promote the colonization of tumor cells in the bone microenvironment.
Animal experiments further verified this association:

Osteoporosis model: The TEAD3-NFATC1 complex in osteoclasts of Malat1 knockout mice (simulating low expression of MALAT1) increased by 40%, and the area of ​​osteolytic lesions expanded by 65%;
Bone metastasis model: The tibia tumor load of tumor-bearing mice with Malat1 knockout increased by 3 times, and the diameter of osteolytic lesions expanded from 1.2mm to 3.5mm, and supplementation of MALAT1 reversed this effect.

4. Therapeutic inspiration: the "double-edged sword" strategy of targeting TEAD3
Osteoporosis treatment

Development of TEAD3 inhibitors (such as small molecule compounds targeting the TEA domain) or MALAT1 mimetics can block the formation of TEAD3-NFATC1 complex and reduce osteoclast activity. At present, inhibitors targeting TEAD palmitoylation sites have entered clinical trials, and in the future they may be transformed into variants that specifically inhibit TEAD3.
Anti-bone metastasis treatment

Combined use of TEAD3 inhibitors with bisphosphonates (such as zoledronic acid) or RANKL antibodies (such as denosumab) may achieve "double blockade": inhibiting osteoclast activity and blocking the "dialogue" between tumor cells and osteoclasts. Preclinical data show that this combination can reduce bone metastases by more than 70%.
Drug resistance warning

Be vigilant about the side effects that may be caused by long-term inhibition of TEAD3, such as compensatory enhancement of osteoblast function leading to heterotopic ossification. In the future, precise drug delivery can be achieved through "time-space specific delivery systems" (such as bone-targeted nanoparticles).

5. Future challenges: the "last mile" from mechanism to clinic

Although the study has revealed the core role of TEAD3, there are still many mysteries to be solved:

Individual differences: Why do some patients not have bone metastasis even if TEAD3 is highly expressed? Are there any other regulatory factors (such as microRNA) that modify the effect?
Combined treatment window: During radiotherapy and chemotherapy, when can TEAD3 inhibition be intervened to maximize the efficacy? How to monitor biomarkers of treatment response?
Cross-species differences: TEAD3 knockout in mouse models leads to 100% bone metastasis, while this proportion in human clinical practice is less than 30%, suggesting the need to establish organoid or PDX models that are closer to the human body.

The game between bone health and tumor bone metastasis is essentially a microscopic war between cell fate determination and metabolic reprogramming. The discovery of TEAD3 not only reveals a new mechanism for osteoclast differentiation, but also reminds us that by regulating the "social network" of transcription factors, it may be possible to press the "pause button" for osteoporosis and tumor bone metastasis at the same time. As Professor Ma Li said: "Targeting TEAD3 may be a 'master key' that can both strengthen the 'walls' of bones and cut off the 'escape channel' of tumor cells." In the future, with the in-depth analysis of the functions of TEAD family members, we will eventually crack the code of this "bone metastasis crisis."